Exact Mass: 767.6063566
Exact Mass Matches: 767.6063566
Found 500 metabolites which its exact mass value is equals to given mass value 767.6063566,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PC(18:2(9Z,12Z)/P-18:1(11Z))
PC(18:2(9Z,12Z)/P-18:1(11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:2(9Z,12Z)/P-18:1(11Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The linoleic acid moiety is derived from seed oils, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(18:2(9Z,12Z)/P-18:1(9Z))
PC(18:2(9Z,12Z)/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:2(9Z,12Z)/P-18:1(9Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The linoleic acid moiety is derived from seed oils, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(18:3(6Z,9Z,12Z)/P-18:0)
PC(18:3(6Z,9Z,12Z)/P-18:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:3(6Z,9Z,12Z)/P-18:0), in particular, consists of one chain of g-linolenic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The g-linolenic acid moiety is derived from animal fats, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(18:3(9Z,12Z,15Z)/P-18:0)
PC(18:3(9Z,12Z,15Z)/P-18:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:3(9Z,12Z,15Z)/P-18:0), in particular, consists of one chain of a-linolenic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(18:3(9Z,12Z,15Z)/P-18:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:3(9Z,12Z,15Z)/P-18:0), in particular, consists of one chain of a-linolenic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(20:3(5Z,8Z,11Z)/P-16:0)
PC(20:3(5Z,8Z,11Z)/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:3(5Z,8Z,11Z)/P-16:0), in particular, consists of one chain of mead acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The mead acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(20:3(8Z,11Z,14Z)/P-16:0)
PC(20:3(8Z,11Z,14Z)/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:3(8Z,11Z,14Z)/P-16:0), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(20:3(8Z,11Z,14Z)/P-16:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(20:3(8Z,11Z,14Z)/P-16:0), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-16:0/20:3(5Z,8Z,11Z))
PC(P-16:0/20:3(5Z,8Z,11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/20:3(5Z,8Z,11Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of mead acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the mead acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-16:0/20:3(5Z,8Z,11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/20:3(5Z,8Z,11Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of mead acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the mead acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-16:0/20:3(8Z,11Z,14Z))
PC(P-16:0/20:3(8Z,11Z,14Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/20:3(8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-16:0/20:3(8Z,11Z,14Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-16:0/20:3(8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:0/18:3(6Z,9Z,12Z))
PC(P-18:0/18:3(6Z,9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/18:3(6Z,9Z,12Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of g-linolenic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the g-linolenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:0/18:3(6Z,9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/18:3(6Z,9Z,12Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of g-linolenic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the g-linolenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:0/18:3(9Z,12Z,15Z))
PC(P-18:0/18:3(9Z,12Z,15Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/18:3(9Z,12Z,15Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of a-linolenic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:0/18:3(9Z,12Z,15Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/18:3(9Z,12Z,15Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of a-linolenic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:1(11Z)/18:2(9Z,12Z))
PC(P-18:1(11Z)/18:2(9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/18:2(9Z,12Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of linoleic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(P-18:1(9Z)/18:2(9Z,12Z))
PC(P-18:1(9Z)/18:2(9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/18:2(9Z,12Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of linoleic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:1(9Z)/18:2(9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/18:2(9Z,12Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of linoleic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(O-16:0/20:4(8Z,11Z,14Z,17Z))
PC(O-16:0/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(O-16:0/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of Palmityl alcohol at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. The Palmityl alcohol moiety is derived from animal fats and vegetable oils, while the eicosatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(o-16:0/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(o-16:0/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of Palmityl alcohol at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. The Palmityl alcohol moiety is derived from animal fats and vegetable oils, while the eicosatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(O-18:2(9Z,12Z)/18:2(9Z,12Z))
PC(O-18:2(9Z,12Z)/18:2(9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(O-18:2(9Z,12Z)/18:2(9Z,12Z)), in particular, consists of one chain of Linoleyl alcohol at the C-1 position and one chain of linoleic acid at the C-2 position. The Linoleyl alcohol moiety is derived from seed oils, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(o-18:2(9Z,12Z)/18:2(9Z,12Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(o-18:2(9Z,12Z)/18:2(9Z,12Z)), in particular, consists of one chain of Linoleyl alcohol at the C-1 position and one chain of linoleic acid at the C-2 position. The Linoleyl alcohol moiety is derived from seed oils, while the linoleic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
1-O-Hexadecyl-2-arachidonoyl-sn-glycero-3-phosphocholine
Carene
Carotene-gamma
Batzelladine A
C42H73N9O4 (767.5785217999999)
A carboxylic ester obtained by the formal condensation of (2aS,3S,4R,7R,8aS)-4-methyl-7-nonyl-2,2a,3,4,6,7,8,8a-octahydro-1H-5,6,8b-triazaacenaphthylene-3-carboxylic acid with the hydroxy group of 4-carbamimidamidobutyl (3R)-3-(9-hydroxynonyl)-1-imino-1,2,3,5,6,7-hexahydropyrrolo[1,2-c]pyrimidine-4-carboxylate. Isolated from a bright red Caribbean sponge, Batzella, it has potential anti-HIV activity.
N-[1-(Acetoxymethyl)-2,3-bis(acetoxy)heptadecyl]-2-acetoxyoctadecanamide
PC(O-16:0/20:4)
PC(O-16:0/20:4)[U]
Arachidonoyl PAF C-16
1-(10-methylhexadecanyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerophosphocholine
PC(O-18:0/18:4(6Z,9Z,12Z,15Z))
N-[(2S,3R,4E,14Z)-1-(beta-D-glucopyranosyloxy)-3-hydroxyoctadeca-4,14-dien-2-yl]henicosanamide
N-[(2S,3R,4E,14Z)-1-(beta-D-galactopyranosyloxy)-3-hydroxyoctadeca-4,14-dien-2-yl]henicosanamide
[3-hexadecoxy-2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[hydroxy-[(2S,3R)-3-hydroxy-2-[[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]amino]octadecoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]amino]octadecoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]amino]octadecoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]amino]octadecoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(2S,3R)-3-hydroxy-2-[[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]amino]octadecoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(2S,3R)-3-hydroxy-2-[[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]amino]octadecoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z)-10-[3-[(Z)-oct-2-enyl]oxiran-2-yl]deca-5,8-dienoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(Z)-7-[3-[(2Z,5Z)-undeca-2,5-dienyl]oxiran-2-yl]hept-5-enoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[4-[3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trienyl]oxiran-2-yl]butanoylamino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5R,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,19S)-19-hydroxyicosa-5,8,11,14-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,18R)-18-hydroxyicosa-5,8,11,14-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5E,8Z,11R,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(2S,3R,4E,14Z)-3-hydroxy-2-[[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]amino]octadeca-4,14-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
1-Arachidonyl-2-palmityl-sn-glycero-3-phosphocholine
A 1-acyl-2-alkyl-sn-glycero-3-phosphocholine in which the acyl and alkyl groups at positions 1 and 2 are specified respectively as arachidonoyl and palmityl.
[2-[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoyl]oxy-3-octoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(5Z,8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z)-N-[(4E,8E,12E)-1,3-dihydroxyicosa-4,8,12-trien-2-yl]dotriaconta-5,8,11,14,17,20,23,26,29-nonaenamide
(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z,38Z,41Z)-N-(1,3-dihydroxyoctan-2-yl)tetratetraconta-8,11,14,17,20,23,26,29,32,35,38,41-dodecaenamide
(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z)-N-[(4E,8E,12E)-1,3-dihydroxyoctadeca-4,8,12-trien-2-yl]tetratriaconta-7,10,13,16,19,22,25,28,31-nonaenamide
2-[2-[(Z)-hexacos-15-enoyl]oxy-3-nonanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
(11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]octatriaconta-11,14,17,20,23,26,29,32,35-nonaenamide
(9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]hexatriaconta-9,12,15,18,21,24,27,30,33-nonaenamide
(11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z,38Z,41Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]tetratetraconta-11,14,17,20,23,26,29,32,35,38,41-undecaenamide
2-[2-[(Z)-hexadec-9-enoyl]oxy-3-nonadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-henicosanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-henicos-11-enoyl]oxy-3-tetradecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-heptadecanoyloxy-2-[(Z)-octadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-docos-13-enoyl]oxy-3-tridecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-tetracos-13-enoyl]oxy-3-undecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-icosanoyloxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-hexadecanoyloxy-2-[(Z)-nonadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-docosanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-icos-11-enoyl]oxy-3-pentadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-heptadec-9-enoyl]oxy-3-octadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]tetraconta-7,10,13,16,19,22,25,28,31,34,37-undecaenamide
(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]octatriaconta-8,11,14,17,20,23,26,29,32,35-decaenamide
(9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]dotetraconta-9,12,15,18,21,24,27,30,33,36,39-undecaenamide
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]hexatriaconta-6,9,12,15,18,21,24,27,30,33-decaenamide
(10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]tetraconta-10,13,16,19,22,25,28,31,34,37-decaenamide
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-(1,3-dihydroxydecan-2-yl)dotetraconta-6,9,12,15,18,21,24,27,30,33,36,39-dodecaenamide
(E)-3-hydroxy-2-[[(18Z,21Z)-2-hydroxytetracosa-18,21-dienoyl]amino]henicos-4-ene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxyicosanoylamino)pentacosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxyhenicosanoylamino)tetracosa-4,8,12-triene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxyhenicos-9-enoyl]amino]tetracosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxyhexacos-11-enoyl]amino]nonadeca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxyicos-11-enoyl]amino]pentacosa-4,8-diene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxyhexacosanoylamino)nonadeca-4,8,12-triene-1-sulfonic acid
(E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyicosa-11,14-dienoyl]amino]pentacos-4-ene-1-sulfonic acid
(E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyhexacosa-11,14-dienoyl]amino]nonadec-4-ene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxypentacosanoylamino)icosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxytetracosanoylamino)henicosa-4,8,12-triene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytricos-11-enoyl]amino]docosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxynonadec-9-enoyl]amino]hexacosa-4,8-diene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxytricosanoylamino)docosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxydocosanoylamino)tricosa-4,8,12-triene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxypentacos-11-enoyl]amino]icosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytetracos-11-enoyl]amino]henicosa-4,8-diene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-(2-hydroxynonadecanoylamino)hexacosa-4,8,12-triene-1-sulfonic acid
(E)-3-hydroxy-2-[[(14Z,16Z)-2-hydroxydocosa-14,16-dienoyl]amino]tricos-4-ene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxydocos-11-enoyl]amino]tricosa-4,8-diene-1-sulfonic acid
[3-[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoxy]-2-octanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] tricosanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-henicosa-11,14-dienoxy]propan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propan-2-yl] pentadecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoxy]propan-2-yl] tridecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (12Z,15Z,18Z)-hexacosa-12,15,18-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] (13Z,16Z)-docosa-13,16-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] (10Z,13Z,16Z)-tetracosa-10,13,16-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonadecoxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoxy]propan-2-yl] undecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoxy]propan-2-yl] (Z)-tridec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoxy]propan-2-yl] (Z)-pentadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecoxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecoxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z)-docosa-13,16-dienoxy]propan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tricosoxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-henicosoxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-henicos-11-enoxy]propan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-[(Z)-icos-11-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-2-icosanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-dodecoxy-2-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-2-[(Z)-icos-11-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-decanoyloxy-3-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-icosoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-decoxy-2-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-dodecanoyloxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[4-[3-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] henicosanoate
[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-octadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-octadecanoyloxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propan-2-yl] heptadecanoate
[3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]-2-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] (Z)-henicos-11-enoate
[3-[(9Z,12Z)-hexadeca-9,12-dienoxy]-2-[(11Z,14Z)-icosa-11,14-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(Z)-hexadec-9-enoxy]-2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-[(Z)-octadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propan-2-yl] (Z)-nonadec-9-enoate
[3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-hexadecoxy-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] nonadecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]propan-2-yl] (Z)-heptadec-9-enoate
[2-hexadecanoyloxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(9Z,12Z)-octadeca-9,12-dienoxy]-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(Z)-hexadec-9-enoyl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-tetradecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]-2-[(Z)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-hexadecoxy-2-[(4Z,7Z,10Z,13Z)-icosa-4,7,10,13-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradec-4-en-2-yl]pentacos-11-enamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadec-4-en-2-yl]docos-11-enamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]henicos-9-enamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytricos-4-en-2-yl]hexadec-7-enamide
(4Z,7Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytricosan-2-yl]hexadeca-4,7-dienamide
(18Z,21Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadecan-2-yl]tetracosa-18,21-dienamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicos-4-en-2-yl]octadec-11-enamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadec-4-en-2-yl]tetracos-11-enamide
(10Z,12Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicosan-2-yl]octadeca-10,12-dienamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptacos-4-en-2-yl]dodec-5-enamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexacos-4-en-2-yl]tridec-8-enamide
(14Z,16Z)-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadecan-2-yl]docosa-14,16-dienamide
(Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadec-4-en-2-yl]tricos-11-enamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicos-4-en-2-yl]octadec-9-enamide
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocosa-4,8-dien-2-yl]heptadecanamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocos-8-en-2-yl]heptadec-9-enamide
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-[[(9E,12E)-octadeca-9,12-dienoyl]amino]henicosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadeca-4,8-dien-2-yl]docosanamide
N-[(2S,3R,4E,6E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,6-dien-2-yl]tetracosanamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocos-4-en-2-yl]heptadec-9-enamide
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,8-dien-2-yl]tricosanamide
N-[(2S,3R,4E,14E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,14-dien-2-yl]henicosanamide
(9E,12E)-N-[(2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicosan-2-yl]octadeca-9,12-dienamide
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,8-dien-2-yl]tetracosanamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadec-4-en-2-yl]tetracos-15-enamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadec-4-en-2-yl]docos-13-enamide
[(2R)-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-[(E)-octadec-1-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-[(E)-octadec-1-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-4,8-dien-2-yl]nonadecanamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]icos-11-enamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicos-8-en-2-yl]octadec-9-enamide
N-[(2S,3R,4E,6E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,6-dien-2-yl]pentacosanamide
[(2R)-3-[(E)-hexadec-1-enoxy]-2-[(8E,11E,14E)-icosa-8,11,14-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]henicosanamide
N-[(2S,3R,4E,6E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,6-dien-2-yl]tricosanamide
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicosa-4,8-dien-2-yl]octadecanamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadec-8-en-2-yl]docos-13-enamide
[(2R)-3-[(E)-hexadec-1-enoxy]-2-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadeca-4,8-dien-2-yl]icosanamide
2-[hydroxy-[(2S,3R)-3-hydroxy-2-[[(5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoyl]amino]pentadecoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadec-8-en-2-yl]tetracos-15-enamide
(E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-8-en-2-yl]icos-11-enamide
N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,8-dien-2-yl]pentacosanamide
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-tetracos-11-enoyl]amino]pentadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]nonadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(18Z,21Z)-tetracosa-18,21-dienoyl]amino]pentadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E)-2-[[(14Z,16Z)-docosa-14,16-dienoyl]amino]-3-hydroxyheptadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-pentacos-11-enoyl]amino]tetradeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]nonadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E,12E)-2-[[(Z)-docos-11-enoyl]amino]-3-hydroxyheptadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-tricos-11-enoyl]amino]hexadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-tridec-8-enoyl]amino]hexacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-octadec-11-enoyl]amino]henicosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E,12E)-2-[[(Z)-dodec-5-enoyl]amino]-3-hydroxyheptacosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]icosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E,12E)-2-[[(Z)-henicos-9-enoyl]amino]-3-hydroxyoctadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]pentacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E)-2-[[(4Z,7Z)-hexadeca-4,7-dienoyl]amino]-3-hydroxytricosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E,12E)-2-[[(Z)-hexadec-7-enoyl]amino]-3-hydroxytricosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]tetracosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(10Z,12Z)-octadeca-10,12-dienoyl]amino]henicosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]pentadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]henicosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxytricosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(8E,12E,16E)-3,4-dihydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]octadeca-8,12,16-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[[(4E,8E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxydocosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(E)-2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]pentadecoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E,12E)-2-[[(Z)-heptadec-9-enoyl]amino]-3-hydroxydocosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]pentadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E,12E)-2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxyoctadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxytricos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(8E,12E)-3,4-dihydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]octadeca-8,12-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(14Z,17Z,20Z)-octacosa-14,17,20-trienoyl]amino]undec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(16Z,19Z,22Z)-triaconta-16,19,22-trienoyl]amino]non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E)-2-[[(11Z,14Z)-henicosa-11,14-dienoyl]amino]-3-hydroxyoctadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]hexacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]icosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxytricosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]pentadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]henicosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[2-[[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]amino]-3-hydroxyheptadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(E)-2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxytridec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]henicosoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(E)-3,4-dihydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]octadec-8-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]henicos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E,12E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxytricosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[2-[[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]amino]-3-hydroxytridecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[3,4-dihydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]octadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O7P+ (767.5702840000001)
2-[hydroxy-[3-hydroxy-2-[[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoyl]amino]undecoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E)-2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxyheptadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[3-hydroxy-2-[[(18Z,21Z,24Z,27Z)-triaconta-18,21,24,27-tetraenoyl]amino]nonoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E,12E)-2-[[(Z)-docos-13-enoyl]amino]-3-hydroxyheptadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[[(4E,8E)-2-[[(15Z,18Z)-hexacosa-15,18-dienoyl]amino]-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
2-[hydroxy-[3-hydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]nonadecoxy]phosphoryl]oxyethyl-trimethylazanium
C44H84N2O6P+ (767.6066674000001)
1-O-HEXADECYL-2-ARACHIDONYL-SN-GLYCERO-3-PHOSPHOCHOLINE
A 1-O-alkyl-2-O-arachidonoyl-sn-glycero-3-phosphocholine where the alkyl group is specified as hexadecyl.
beta-D-galactosyl-(1<->1)-N-henicosanoyl-(4E,14Z)-sphingadienine
A galactosylceramide obtained by formal condensation of the carboxy group of henicosanoic acid with the amino group of beta-D-galactosyl-(1<->1)-(4E,14Z)-sphingadienine.
beta-D-glucosyl-(1<->1)-N-henicosanoyl-(4E,14Z)-sphingadienine
A beta-D-glucosylceramide obtained by formal condensation of the carboxy group of henicosanoic acid with the amino group of beta-D-glucosyl-(1<->1)-(4E,14Z)-sphingadienine.
1-octadecadienoyl-2-octadecenoyl-sn-glycero-3-phosphocholine
A phosphatidylcholine 36:3 in which the acyl groups at positions 1 and 2 are specified as octadecadienoyl and octadecenoyl respectively.
phosphatidylcholine O-36:4
A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 36 carbons and 4 double bonds.
MePC(35:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(38:3)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(39:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
9-{4-[(4-carbamimidamidobutoxy)carbonyl]-1-imino-2h,3h,5h,6h,7h-pyrrolo[1,2-c]pyrimidin-3-yl}nonyl 6-methyl-10-nonyl-7,9,12-triazatricyclo[6.3.1.0⁴,¹²]dodec-7-ene-5-carboxylate
C42H73N9O4 (767.5785217999999)
2-(acetyloxy)-n-[1,3,4-tris(acetyloxy)octadecan-2-yl]octadecanimidic acid
9-[(3r)-4-[(4-carbamimidamidobutoxy)carbonyl]-1-imino-2h,3h,5h,6h,7h-pyrrolo[1,2-c]pyrimidin-3-yl]nonyl (1s,4s,5s,6r,10r)-6-methyl-10-nonyl-7,9,12-triazatricyclo[6.3.1.0⁴,¹²]dodec-7-ene-5-carboxylate
C42H73N9O4 (767.5785217999999)